The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With Hypertension
Open accessAbstract
Hypertension is associated with endothelial dysfunction that is attributable to oxidative stress and a proinflammatory state. Under these conditions, enhanced expression of cyclooxygenase-2 might lead to increased production of vasoconstrictor prostanoids and reactive oxygen species that reduce the bioavailability of endothelium-derived nitric oxide. To investigate the contribution of cyclooxygenase-2 activity to endothelial dysfunction in human hypertension, we evaluated brachial artery vasodilator function by ultrasound in 29 hypertensive patients before and after treatment with the selective cyclooxygenase-2 inhibitor celecoxib or placebo in a randomized, double-blind study. Brachial artery flow–mediated dilation improved from a baseline of 7.9±4.5% to 9.9±5.1% ( P =0.005) 3 hours after the first dose and to 10.1±6.1% ( P =0.006) after 1 week of treatment with celecoxib. In contrast, placebo treatment had no significant effect on flow-mediated dilation (8.1±4.4%, 8.3±3.5%, and 8.0±3.2%, respectively). Neither treatment altered nitroglycerin-mediated dilation, extent of reactive hyperemia, or baseline arterial diameter. Celecoxib treatment had no significant effect on the urinary concentrations of F 2 isoprostane or thromboxane metabolites. However, urinary concentrations of the prostacyclin metabolite 2,3-dinor-6-ketoprostglandin F 1α were significantly lower after 1 week of celecoxib treatment. Thus, cyclooxygenase-2 products contribute to endothelial dysfunction in hypertension, and treatment with a cyclooxygenase-2 inhibitor could have a beneficial effect in this setting. However, cyclooxygenase-2 inhibition also has an adverse effect on prostacyclin production that could promote thrombosis, and the net clinical consequences of improved endothelial function versus loss of prostacyclin merits further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Gokce, N., Keaney, J. F., Frei, B., Holbrook, M., Olesiak, M., Zachariah, B. J., Leeuwenburgh, C., Heinecke, J. W., & Vita, J. A. (1999) · Circulation · doi:10.1161/01.cir.99.25.3234 · Cited by 387
Self-citation
Cited by
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
Warner, T. D., & Mitchell, J. A. (2004) · The FASEB Journal · doi:10.1096/fj.03-0645rev · Cited by 614
COX-2 and beyond: approaches to prostaglandin inhibition in human disease
FitzGerald, G. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1225 · Cited by 518
Ikonomidis, I., Lekakis, J. P., Nikolaou, M., Paraskevaidis, I., Andreadou, I., Kaplanoglou, T., Katsimbri, P., Skarantavos, G., Soucacos, P. N., & Kremastinos, D. T. (2008) · Circulation · doi:10.1161/circulationaha.107.731877 · Cited by 307
Endothelium‐dependent contractions in hypertension
Vanhoutte, P. M., Feletou, M., & Taddei, S. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706042 · Cited by 284
Cyclooxygenase Inhibition and Cardiovascular Risk
Antman, E. M., DeMets, D., & Loscalzo, J. (2005) · Circulation · doi:10.1161/circulationaha.105.568451 · Cited by 282
Metadata
- Authors
- Widlansky, M. E., Price, D. T., Gokce, N., Eberhardt, R. T., Duffy, S. J., Holbrook, M., Maxwell, C., Palmisano, J., Keaney, J. F., Morrow, J. D., & Vita, J. A.
- Venue
- Hypertension
- Published
- 2003-09
- Volume
- 42
- Issue
- 3
- Pages
- 310-315
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2129333373
- Cited by
- 158
- References
- 3
- FWCI
- 10.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With Hypertension. https://app.cochat.ai/papers/10.1161/01.hyp.0000084603.93510.28
- The paper
- Widlansky, M. E., Price, D. T., Gokce, N., Eberhardt, R. T., Duffy, S. J., Holbrook, M., Maxwell, C., Palmisano, J., Keaney, J. F., Morrow, J. D., & Vita, J. A. (2003). Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With Hypertension. Hypertension. https://doi.org/10.1161/01.hyp.0000084603.93510.28
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.